MX2019012461A - Anticuerpo anti-pd-l1 y uso del mismo. - Google Patents
Anticuerpo anti-pd-l1 y uso del mismo.Info
- Publication number
- MX2019012461A MX2019012461A MX2019012461A MX2019012461A MX2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A MX 2019012461 A MX2019012461 A MX 2019012461A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fully human
- disclosed
- affinity
- human anti
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
Se dan a conocer anticuerpos anti-PD-L1 completamente humanos y sus aplicaciones correspondientes. Los anticuerpos completamente humanos tienen la capacidad de enlazarse específicamente a PD-L1 de humano. Los anticuerpos se obtuvieron al emplear una técnica de prospección basada en una genoteca de despliegue en levadura y también por medio de la maduración de la afinidad para mejorar adicionalmente su afinidad por PD-L1. Los anticuerpos anti-PD-L1 completamente humanos dados a conocer muestran buena especificidad, afinidad y estabilidad. Éstos tienen la capacidad de mejorar la actividad de células T al enlazarse a células T activadas, mientras que inhiben significativamente el crecimiento de tumores. Los anticuerpos anti-PD-L1 completamente humanos dados a conocer se pueden usar en el diagnóstico y el tratamiento de cánceres relacionados con PD-L1 y otras enfermedades asociadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2017028206 | 2017-04-18 | ||
PCT/US2018/028206 WO2018195226A1 (en) | 2017-04-18 | 2018-04-18 | Anti-pd-l1 antibody and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012461A true MX2019012461A (es) | 2019-12-11 |
Family
ID=63856823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012461A MX2019012461A (es) | 2017-04-18 | 2018-04-18 | Anticuerpo anti-pd-l1 y uso del mismo. |
Country Status (16)
Country | Link |
---|---|
US (1) | US20210115143A1 (es) |
EP (1) | EP3612565A4 (es) |
JP (2) | JP2020517239A (es) |
KR (1) | KR102323960B1 (es) |
CN (1) | CN110856446A (es) |
AU (1) | AU2018256392B2 (es) |
BR (1) | BR112019021828B1 (es) |
CA (1) | CA3059447A1 (es) |
CL (1) | CL2019002953A1 (es) |
CO (1) | CO2019012118A2 (es) |
EA (1) | EA201900443A1 (es) |
MA (1) | MA50038A (es) |
MX (1) | MX2019012461A (es) |
PH (1) | PH12019502302A1 (es) |
SG (1) | SG11201909041SA (es) |
WO (1) | WO2018195226A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CN113646330A (zh) * | 2018-11-14 | 2021-11-12 | 鲁比克治疗股份有限公司 | 工程化cd25多肽及其用途 |
CN109929037B (zh) * | 2019-04-01 | 2023-03-17 | 华博生物医药技术(上海)有限公司 | 针对程序性死亡配体的结合物及其应用 |
US20220195049A1 (en) * | 2019-04-11 | 2022-06-23 | Scripps Korea Antibody Institute | Antibodies against programmed death-ligand 1 and uses thereof |
MX2021004897A (es) * | 2019-04-26 | 2021-06-18 | I Mab Biopharma Us Ltd | Anticuerpos pd-l1 humano. |
WO2022006091A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030113316A1 (en) * | 2001-07-25 | 2003-06-19 | Kaisheva Elizabet A. | Stable lyophilized pharmaceutical formulation of IgG antibodies |
CN104479018B (zh) * | 2008-12-09 | 2018-09-21 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
AU2014339900B2 (en) * | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
KR102395498B1 (ko) * | 2014-01-06 | 2022-05-09 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용 |
US9688754B2 (en) * | 2014-02-20 | 2017-06-27 | Alder Biopharmaceuticals, Inc. | Anti-ACTH antibodies and use thereof |
CN105777906B (zh) * | 2014-12-19 | 2019-04-23 | 苏州丁孚靶点生物技术有限公司 | 抗pd-l1全人抗体及其应用 |
EP3268392A2 (en) * | 2015-03-13 | 2018-01-17 | CytomX Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
WO2018080812A1 (en) * | 2016-10-30 | 2018-05-03 | Henlix, Inc. | Anti-pd-l1 antibodies and variants |
-
2018
- 2018-04-18 CN CN201880025898.4A patent/CN110856446A/zh active Pending
- 2018-04-18 AU AU2018256392A patent/AU2018256392B2/en active Active
- 2018-04-18 US US16/606,647 patent/US20210115143A1/en not_active Abandoned
- 2018-04-18 KR KR1020197032419A patent/KR102323960B1/ko active IP Right Grant
- 2018-04-18 EA EA201900443A patent/EA201900443A1/ru unknown
- 2018-04-18 JP JP2019556600A patent/JP2020517239A/ja active Pending
- 2018-04-18 MA MA050038A patent/MA50038A/fr unknown
- 2018-04-18 WO PCT/US2018/028206 patent/WO2018195226A1/en unknown
- 2018-04-18 CA CA3059447A patent/CA3059447A1/en active Pending
- 2018-04-18 MX MX2019012461A patent/MX2019012461A/es unknown
- 2018-04-18 SG SG11201909041S patent/SG11201909041SA/en unknown
- 2018-04-18 BR BR112019021828-9A patent/BR112019021828B1/pt active IP Right Grant
- 2018-04-18 EP EP18788069.5A patent/EP3612565A4/en active Pending
-
2019
- 2019-10-07 PH PH12019502302A patent/PH12019502302A1/en unknown
- 2019-10-16 CL CL2019002953A patent/CL2019002953A1/es unknown
- 2019-10-29 CO CONC2019/0012118A patent/CO2019012118A2/es unknown
-
2022
- 2022-11-07 JP JP2022178282A patent/JP2023025003A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112019021828A2 (pt) | 2020-03-24 |
PH12019502302A1 (en) | 2020-09-21 |
CO2019012118A2 (es) | 2020-04-01 |
US20210115143A1 (en) | 2021-04-22 |
AU2018256392B2 (en) | 2024-05-16 |
JP2020517239A (ja) | 2020-06-18 |
EP3612565A1 (en) | 2020-02-26 |
AU2018256392A1 (en) | 2019-10-17 |
CA3059447A1 (en) | 2018-10-25 |
MA50038A (fr) | 2020-07-08 |
KR20190141169A (ko) | 2019-12-23 |
CN110856446A (zh) | 2020-02-28 |
EP3612565A4 (en) | 2021-06-16 |
SG11201909041SA (en) | 2019-11-28 |
CL2019002953A1 (es) | 2020-01-10 |
WO2018195226A1 (en) | 2018-10-25 |
JP2023025003A (ja) | 2023-02-21 |
EA201900443A1 (ru) | 2020-03-06 |
BR112019021828B1 (pt) | 2022-09-20 |
KR102323960B1 (ko) | 2021-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502302A1 (en) | Anti-pd-l1 antibody and use thereof | |
PH12019500545A1 (en) | Cd3 binding antibodies | |
JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
MX2021006786A (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y metodos de uso de los mismos. | |
MX2018016404A (es) | Anticuerpos de union a cd3. | |
MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
PH12017500994A1 (en) | Anti-pd-1 antibodies and methods of use thereof | |
MX2021013336A (es) | Anticuerpos y receptores de antigeno quimericos especificos para cd19. | |
MX360543B (es) | Anticuerpos st-2 humanos solubles y ensayos. | |
EA201491700A1 (ru) | Человеческие антитела к cd27, методы и применение | |
NZ743124A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
ZA201707869B (en) | Anti-ntb-a antibodies and related compositions and methods | |
MX2020002198A (es) | Anticuerpos anti-cd166 activables y métodos de uso de los mismos. | |
PH12014502641B1 (en) | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof | |
EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
NZ631543A (en) | Antibodies to bradykinin b1 receptor ligands | |
WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
MY187325A (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
MX2021009722A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
WO2015161311A3 (en) | Humanized anti-tf-antigen antibodies | |
MX2021009727A (es) | Anticuerpos que se unen al tejido tumoral para diagnóstico y tratamiento. | |
MX2020008730A (es) | Regímenes de dosificación de anticuerpo b7-h4. | |
TN2017000451A1 (en) | Igf-1r antibody and its use for the diagnosis of cancer | |
MX2018011169A (es) | Metodo para prevenir la enfermedad del injerto contra huesped. |